Table 2 Treatment regimen stratified by whether the patient was treated with or without anti-HER2 therapy
|  | All (N = 128) |
|---|---|
Anti-HER2 therapy | 105 (82.0) |
 Trastuzumab + pertuzumab + chemotherapy | 32 (25.0) |
 Trastuzumab + pertuzumab + endocrine therapy | 1 (0.8) |
 Trastuzumab + pertuzumab | 3 (2.3) |
 Trastuzumab + chemotherapy | 16 (12.5) |
 Trastuzumab + endocrine therapy | 9 (7.0) |
 Trastuzumab alone | 10 (7.8) |
 Lapatinib + capecitabine | 34 (26.6) |
Regimens without anti-HER2 therapy | 23 (18.0) |
 Bevacizumab + paclitaxel | 12 (9.4) |
 Other chemotherapy | 5 (3.9) |
 Everolimus + exemestane | 2 (1.6) |
 Endocrine alone | 4 (3.1) |